ABSTRACT
Objective
Describe outcomes associated with bolus and continuous infusions of hypertonic saline (HTS) in children with severe traumatic brain injury (TBI).
Methods
IRB-approved, single-center, retrospective review of children admitted between January 1, 2012 to August 30, 2018 with a diagnosis of severe TBI who received HTS.
Results
Forty-five children (age 9.3 ± 5.8 yr; 60% male) met inclusion criteria. One-hundred eighty-nine equiosmolar bolus doses of HTS were administered to 43 patients (3% HTS, n = 84 doses; 6% HTS, n = 38 doses; 12% HTS, n = 67 doses) for episodes of acute intracranial hypertension (pressure above 20 mmHg). Significant reductions in ICP were observed at 30, 60, and 120 min following HTS boluses with the greatest decrease observed in patients receiving 12%. Thirty-four patients received a continuous infusion of HTS. Higher concentrations of HTS were associated with a more favorable fluid balance (p < .001), fewer episodes of pulmonary edema (p = .003), and higher intake of protein and energy (p < .001).
Conclusions
Equiosmolar bolus doses of concentrated HTS were associated with significant reductions in ICP. Benefits of higher concentrations of continuous HTS may include improved fluid balance, less pulmonary edema, and greater amounts of protein and energy intake.
Acknowledgments
The authors would like to acknowledge Colin Maehler, PharmD Candidate 2021 for his valuable contribution to data collection.
Key words for indexing: hyperosmolar therapy, hypertonic saline, traumatic brain injury, children, intensive care
Disclosures/Conflict of Interest
The authors have no financial interests or affiliations with institutions, organizations, or companies relevant to the manuscript. Additionally, financial associations involving our spouse, partner, or children are not present.
Details Page
As the corresponding author, I confirm that this manuscript complies with all instructions to authors and that authorship requirements have been met and the final manuscript was approved by all authors.
This manuscript has not been published elsewhere and is not under consideration by another journal. We have adhered to ethical guidelines and have received IRB approval for this work. A statement regarding IRB approval has been placed within the manuscript.
Disclosure statement
Conflict of Interest statements for all authors are listed below:
Dr Sabers has nothing to disclose
Dr Reiter has nothing to disclose
Ms Skillman has nothing to disclose
Dr DeMasellis has nothing to disclose